{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04879043",
            "orgStudyIdInfo": {
                "id": "HDP-101-01"
            },
            "organization": {
                "fullName": "Heidelberg Pharma AG",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma",
            "officialTitle": "A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma",
            "therapeuticArea": [
                "Other"
            ],
            "study": "study-to-assess-safety-of-hdp-in-patients-with-relapsed-refractory-multiple-myeloma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-02-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-04-23",
            "studyFirstSubmitQcDate": "2021-05-04",
            "studyFirstPostDateStruct": {
                "date": "2021-05-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Heidelberg Pharma AG",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.",
            "detailedDescription": "The study will consists of two parts: a Part 1 dose escalation phase and a Part 2a expansion phase for safety, tolerability, PK, PD, and clinical activity testing. The study will enroll subjects with relapsed/refractory MM or other plasma cell disorders expressing BCMA. An adaptive 2-parameter Bayesian logistic regression model (BLRM) for dose-escalation with overdose control will be used in the dose-escalation phase for determination of the MTD or the RP2D. Dose-expansion phase of the study aims to collect preliminary evidence of antitumor activity and to confirm the safety of the HDP-101 as a monotherapy."
        },
        "conditionsModule": {
            "conditions": [
                "Multiple Myeloma",
                "Plasma Cell Disorder"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Eligible patients will be enrolled and treated with intravenous HDP-101 every 3 weeks. In Phase 1 dose-escalation part from Cohort 6 additional treatment arms are introduced for dose-optimization purposes with dosing every 3 weeks, split dosing weekly or split dosing in the first cycle on Day1 and Day8.\n\nA Bayesian logistic regression model will be used to guide dose-escalation during Phase 1 and select the best dose for the Phase 2a of the study.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 78,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "HDP-101",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive HDP-101 intravenously in a 21 day cycle until disease progression, intolerable toxicity, Investigator's discretion or patient withdrawal.\n\nDuring the phase 1 tolerability of different dose levels will be evaluated. During the phase 2a dose expansion part the recommended phase 2 dose (RP2D) of HDP-101 will be administered.",
                    "interventionNames": [
                        "Drug: HDP-101"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "HDP-101",
                    "description": "HDP-101 is available as lyophilized white powder for preparation of infusion.",
                    "armGroupLabels": [
                        "HDP-101"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of patients who experience dose-limiting toxicity (DLT) during the first cycle of treatment - Part 1 as defined in Clinical Study Protocol",
                    "timeFrame": "Up to Day 21 (from first dose)"
                },
                {
                    "measure": "Objective response rate (ORR)",
                    "description": "Proportion of enrolled subjects who achieve a partial response (PR) or better, i.e. stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and PR, according to the IMWG criteria.",
                    "timeFrame": "Through study completion, an average of 1 year"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Assess the safety and tolerability of HDP-101",
                    "description": "Number of patients with serious and non-serious adverse events grouped by system organ class and preferred terms based on Common Terminology Criteria for Adverse Events (CTCAE v 5.0) classification.",
                    "timeFrame": "Through study completion, an average of 1 year"
                },
                {
                    "measure": "To assess the anticancer activity of HDP-101 in terms of time-to-event (TTE)",
                    "description": "Clinical efficacy of HDP-101 measured by Progression Free Survival (PFS) and Overall Survival (OS).",
                    "timeFrame": "Through study completion, an average of 1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female aged \u226518 years.\n* Life expectancy \\>12 weeks.\n* Eastern Cooperative Oncology Group Performance Status (PS) of 0 to 2.\n* A confirmed diagnosis of active MM according to the diagnostic criteria established by the International Myeloma Working Group (IMWG).\n* Must have undergone SCT or is considered transplant ineligible.\n* Must have undergone prior treatments with antimyeloma therapy which must have included an immunomodulatory drug, proteasome inhibitor, and anti-CD38 treatment, alone or in combination. In addition, the patient should either refractory or intolerant to any established standard of care therapy providing a meaningful clinical benefit for the patient assessed by the Investigator.\n* Measurable disease as per IMWG criteria.\n* Adequate organ system function as defined in protocol.\n\nExclusion Criteria:\n\n* For patient entering the Phase 2a part only: Prior treatment with any approved or experimental BCMA-targeting modalities are not allowed.\n* Known central nervous system involvement.\n* Plasma cell leukemia.\n* History of congestive heart failure.\n* Autologous or allogenic SCT within 12 weeks before the first infusion or is planning for autologous SCT.\n* Symptomatic graft versus host disease post allogenic hemopoietic cell transplant within 12 months prior to the first study treatment infusion.\n* Radiotherapy within 21 days prior to the first study treatment infusion.\n* History of any other malignancy known to be active.\n* Known human immunodeficiency virus infection.\n* Patients with active infection requiring systemic anti-infective.\n* Patients with positive test results for hepatitis B surface antigen or Hepatitis B core antigen.\n* Patients with positive test results for hepatitis C virus (HCV) infection.\n* Current active liver or biliary disease.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Andr\u00e1s Strassz, MD",
                    "role": "CONTACT",
                    "phone": "+ 49 6203 1009 0",
                    "email": "clinical@hdpharma.com"
                }
            ],
            "locations": [
                {
                    "facility": "Winship Cancer Institute of Emory University",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30322",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Mount Sinai, The Tisch Cancer Instutute",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Charit\u00e9 - Campus Benjamin Franklin Med. Klinik m.S. H\u00e4matologie, Onkologie",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Berlin",
                    "zip": "12203",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 52.52437,
                        "lon": 13.41053
                    }
                },
                {
                    "facility": "Klinikum Chemnitz gGmbH, Klinik f. Innere Medizin III",
                    "status": "RECRUITING",
                    "city": "Chemnitz",
                    "zip": "09116",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 50.8357,
                        "lon": 12.92922
                    }
                },
                {
                    "facility": "Asklepios Klinik Altona, Haematologie und internistische Onkologie",
                    "status": "RECRUITING",
                    "city": "Hamburg",
                    "zip": "22763",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 53.57532,
                        "lon": 10.01534
                    }
                },
                {
                    "facility": "Universit\u00e4tsklinikum Heidelberg",
                    "status": "RECRUITING",
                    "city": "Heidelberg",
                    "zip": "69120",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 49.40768,
                        "lon": 8.69079
                    }
                },
                {
                    "facility": "Universit\u00e4tsklinikum Schleswig-Holstein",
                    "status": "RECRUITING",
                    "city": "Kiel",
                    "zip": "24105",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 54.32133,
                        "lon": 10.13489
                    }
                },
                {
                    "facility": "Universit\u00e4tsklinikum K\u00f6ln",
                    "status": "RECRUITING",
                    "city": "K\u00f6ln",
                    "zip": "50937",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 50.93333,
                        "lon": 6.95
                    }
                },
                {
                    "facility": "UKSH Campus L\u00fcbeck Klinik f\u00fcr H\u00e4matologie und Onkologie",
                    "status": "RECRUITING",
                    "city": "L\u00fcbeck",
                    "zip": "23538",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 53.86893,
                        "lon": 10.68729
                    }
                },
                {
                    "facility": "Universit\u00e4tsklinikum Mainz",
                    "status": "WITHDRAWN",
                    "city": "Mainz",
                    "zip": "55131",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 49.98419,
                        "lon": 8.2791
                    }
                },
                {
                    "facility": "Semmelweis University, Belgyogyaszati es Onkologiai Klinika",
                    "status": "RECRUITING",
                    "city": "Budapest",
                    "zip": "1083",
                    "country": "Hungary",
                    "geoPoint": {
                        "lat": 47.49801,
                        "lon": 19.03991
                    }
                },
                {
                    "facility": "National Institute of Oncology, Department of Oncological Internal Medicine",
                    "status": "RECRUITING",
                    "city": "Budapest",
                    "zip": "1122",
                    "country": "Hungary",
                    "geoPoint": {
                        "lat": 47.49801,
                        "lon": 19.03991
                    }
                },
                {
                    "facility": "Pratia Onkologia Katowice",
                    "status": "RECRUITING",
                    "city": "Katowice",
                    "zip": "40-519",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 50.25841,
                        "lon": 19.02754
                    }
                },
                {
                    "facility": "Szpital Wojewodzki w Opolu",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Opole",
                    "zip": "45-061",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 50.67211,
                        "lon": 17.92533
                    }
                },
                {
                    "facility": "Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi",
                    "status": "NOT_YET_RECRUITING",
                    "city": "\u0141\u00f3d\u017a",
                    "zip": "93-513",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 51.75,
                        "lon": 19.46667
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "type": "BACKGROUND",
                    "citation": "Strassz A, Raab MS, Orlowski RZ, Kulke M, Schiedner G, Pahl A. A First in Human Study Planned to Evaluate HDP-101, an Anti-BCMA Amanitin Antibody-Drug Conjugate with a New Payload and a New Mode of Action, in Multiple Myeloma. Blood 2020; 136 (Supplement 1): 34. doi: https://doi.org/10.1182/blood-2020-142285"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009101",
                    "term": "Multiple Myeloma"
                },
                {
                    "id": "D000054219",
                    "term": "Neoplasms, Plasma Cell"
                },
                {
                    "id": "D000010265",
                    "term": "Paraproteinemias"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000020141",
                    "term": "Hemostatic Disorders"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000001796",
                    "term": "Blood Protein Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12058",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13178",
                    "name": "Paraproteinemias",
                    "asFound": "Plasma Cell Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5077",
                    "name": "Blood Protein Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3947",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}